Novo Nordisk A/S
NOVC.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$165.72B
Close$
Share Statistics
| Market cap | $165.72 Billion |
|---|---|
| Enterprise Value | $281.83 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 52.62% |
|---|---|
| Return on Assets | 19.57% |
| Return on Invested Capital | 40.14% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.86 |
| Enterprise Value to EBIT | 1.97 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.57 |
| Debt to Equity | 0.73 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Novo Nordisk
68,794 employees
CEO: Lars Fruergaard Joergensen Novo Nordisk A/S, along with its affiliated companies, focuses on the discovery, production, and global sale of pharmaceutical goods. Its market presence extends across Europe, the Middle East, Africa, North America, and various Asian te...